Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 15, 2020

View Archived Issues

New targets, new booster for CAR-T cells

As nanoparticles, vitamins fight sepsis

Targeting SMPD1 ameliorates leptin resistance-derived endothelial dysfunction in rats

ViiV Healtcare's Dovato receives approval in Japan for HIV infection

Cynata receives approval for its U.K. phase II study in critical limb ischemia

Kannalife presents additional data regarding the MOA of its leading candidate KLS-13019

NantKwest announces phase I data for PD-L1t.haNK

Alexion plans to initiate pivotal phase III CHAMPION-ALS study of Ultomiris in ALS

TROP2-targeted photoimmunotherapy shows promise in preclinical models

Zuclomiphene reduces moderate to severe hot flashes in men with prostate cancer on ADT

TCP-25 wound gel targets wound infection and inflammation in vivo

Cts Biopharma describes new anti-marinobufagenin antibodies

Cugene patents interleukin-2 variants

Kite Pharma discloses vectors encoding recombinant therapeutic T cells receptors

New gemcitabine prodrugs discovered at Shanghai Changchengyiyaokeji

Conatus Pharmaceuticals discovers caspase inhibitors

New STING receptor agonists discovered at Eternity Bioscience

Subtypes take on new importance as KRAS inhibitors proceed

NOTCH3 genetic variant found as a risk factor of stroke

Investigators report ZUMA-2 results with KTE-X19 in mantle cell lymphoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...